[HTML][HTML] The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: an open-label …
S Weisshaar, B Litschauer, S Bucher, M Riesenhuber… - Medicine, 2016 - journals.lww.com
Background: There is a need to optimize pharmacological treatment in patients with acute
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
[HTML][HTML] The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label …
S Weisshaar, B Litschauer, S Bucher, M Riesenhuber… - Medicine, 2016 - ncbi.nlm.nih.gov
Background: There is a need to optimize pharmacological treatment in patients with acute
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label …
S Weisshaar, B Litschauer, S Bucher… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Background There is a need to optimize pharmacological treatment in patients with acute
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label …
S Weisshaar, B Litschauer, S Bucher, M Riesenhuber… - Medicine, 2016 - europepmc.org
Background There is a need to optimize pharmacological treatment in patients with acute
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label …
S Weisshaar, B Litschauer, S Bucher, M Riesenhuber… - Medicine, 2016 - europepmc.org
Background There is a need to optimize pharmacological treatment in patients with acute
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …